Following a successful roadshow with Institutional Investors in London, CHEPLAPHARM Arzneimittel GmbH was able to issue another loan (TLB market) in mid-November.
This will provide the company with the liquid funds to consistently pursue its sustainable M&A strategy
“Just in the months of August and September, "said Cheplapharm CEO Sebastian F. Braun," we closed another five acquisitions and are planning one last deal later this year. This will help to further diversify our product portfolio. The new financing options put us in a position to vigorously pursue our growth strategy.“
Prerequisites for the second, successful coup on the London capital market were external ratings by S&P and Moody's and the support of an international banking group.
Commenting on the successful mission in London, Jens Rothstein, CFO, said: "We are very pleased with the continued demand and investor confidence in the Cheplapharm business model and our growth strategy. Thanks to the new credit facilities at very attractive rates, we now have the necessary flexibility and liquidity to further develop the company."
Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)cheplapharm.com